COVID-19 Anosmia Study

PHASE2CompletedINTERVENTIONAL
Enrollment

139

Participants

Timeline

Start Date

July 15, 2020

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
AnosmiaCovid19
Interventions
DRUG

Omega-3 Fatty Acid Supplement

Participants randomized to this arm will be instructed to take two of the softgels they received per day for 6 weeks. They will receive softgels containing 1,000 mg of omega-3 fatty acid. 1000 mg of omega-3 fatty acid blend including 683 mg Eicosapentaenoic Acid and 252 mg Docosahexaenoic Acid

DRUG

Placebo/Control

Patients randomized to this arm will also be instructed to take two of the softgels they received per day for 6 weeks. They will receive placebo softgels that are indistinguishable from those containing fish oil.

Trial Locations (1)

10029

Mount Sinai Hospital, New York

All Listed Sponsors
lead

Icahn School of Medicine at Mount Sinai

OTHER

NCT04495816 - COVID-19 Anosmia Study | Biotech Hunter | Biotech Hunter